iRhythm Gains CDC Coverage Decision for Cardiac Monitoring Devices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy IRTC?
Source: seekingalpha
- Policy Boost: The CDC's finalized local coverage determination for cardiac monitoring devices, including iRhythm's Zio ECG system, is expected to enhance market acceptance and sales potential for the company.
- Analyst Optimism: BTIG analyst Marie Thibault highlighted in a research note that this decision alleviates investor confusion regarding Medicare proposals, viewing the update as a positive for iRhythm with a Buy rating and a target price of $185.
- Market Expectations: The analyst anticipates that the other two Medicare Administrative Contractors (MACs), Palmetto and CGS, will follow suit, further strengthening iRhythm's competitive position and business stability in the market.
- Financial Outlook: iRhythm forecasts 2026 revenue between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, indicating strong growth potential supported by the new policy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRTC
Wall Street analysts forecast IRTC stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 120.660
Low
205.00
Averages
222.00
High
244.00
Current: 120.660
Low
205.00
Averages
222.00
High
244.00
About IRTC
iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
iRhythm Gains CDC Coverage Decision for Cardiac Monitoring Devices
- Policy Boost: The CDC's finalized local coverage determination for cardiac monitoring devices, including iRhythm's Zio ECG system, is expected to enhance market acceptance and sales potential for the company.
- Analyst Optimism: BTIG analyst Marie Thibault highlighted in a research note that this decision alleviates investor confusion regarding Medicare proposals, viewing the update as a positive for iRhythm with a Buy rating and a target price of $185.
- Market Expectations: The analyst anticipates that the other two Medicare Administrative Contractors (MACs), Palmetto and CGS, will follow suit, further strengthening iRhythm's competitive position and business stability in the market.
- Financial Outlook: iRhythm forecasts 2026 revenue between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, indicating strong growth potential supported by the new policy.
See More
iRhythm Exceeds Q1 2026 Earnings Expectations
- Significant Revenue Growth: iRhythm reported $199.4 million in revenue for Q1 2026, representing a 26% year-over-year increase that exceeded analyst expectations, demonstrating strong performance across cardiology and primary care, thereby solidifying its market position.
- Improved Adjusted EBITDA: The adjusted EBITDA margin for Q1 improved to 7.1%, reflecting an 880 basis point increase from the previous quarter, which highlights the company's success in manufacturing automation and workflow optimization, and is expected to drive future profitability enhancements.
- Market Expansion Strategy: The company achieved its best quarter in history in the U.K. while also receiving an updated reimbursement framework in Japan, indicating that its international market expansion strategy is yielding results and is likely to enhance revenue streams in the future.
- Optimistic Outlook: iRhythm raised its full-year 2026 revenue guidance to $875 million to $885 million and anticipates Q2 revenue in the range of $218 million to $220 million, reflecting management's confidence in future performance and sustained market demand.
See More
iRhythm Technologies Set to Announce Q1 Earnings on April 30
- Earnings Announcement: iRhythm Technologies is set to release its Q1 2023 earnings on April 30 after market close, with a consensus EPS estimate of -$0.64, reflecting a 32.6% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $194.09 million, representing a 22.3% year-over-year increase, which highlights the company's positive performance in market demand and product innovation, potentially driving future growth.
- Historical Performance Review: Over the past two years, iRhythm has exceeded EPS estimates 50% of the time and revenue estimates 100% of the time, demonstrating the company's reliability and execution capability in financial forecasting.
- Future Outlook: iRhythm aims for a revenue target of $870 million to $880 million by 2026 while continuing to expand its innovations in artificial intelligence and mobile cardiac telemetry (MCT), showcasing the company's confidence and strategic positioning for future growth.
See More
Investigation into iRhythm Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting shareholder rights and corporate governance.
- Legal Fee Arrangement: The firm promises to handle the case on a contingent fee basis, meaning shareholders can pursue legal remedies without incurring upfront legal costs, thereby reducing the financial risk of participation.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately helps to increase shareholder value and promote long-term company growth.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its strength in protecting investor rights.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as indicated by a federal securities lawsuit alleging failure to disclose the true purpose of the Zio AT monitor.
- Disclosure Failures: The lawsuit claims that insiders at iRhythm repeatedly touted the potential growth of the Zio AT as an innovative product without clarifying that it was intended for high-risk patients, leading investors to misunderstand its market potential.
- Stock Price Impact: These misleading statements resulted in iRhythm's common stock trading at artificially inflated prices during relevant periods, potentially causing financial losses for shareholders and damaging the company's market reputation.
- Call to Action for Shareholders: Kuehn Law urges shareholders who purchased IRTC stock before November 5, 2021, to contact them promptly to assert their rights and contribute to the integrity of the financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether certain executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that insiders failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Impact of Misrepresentation: The lawsuit claims that iRhythm executives repeatedly touted the potential growth of the Zio AT as an innovative product without clarifying its primary use for high-risk patients, resulting in artificially inflated stock prices during relevant periods, which misled investors.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased IRTC stock prior to November 5, 2021, to contact their attorney promptly to protect their rights, highlighting the urgency and necessity of legal action in this matter.
- Call for Market Integrity: Kuehn Law emphasizes the importance of shareholder voices in maintaining the integrity and fairness of financial markets, encouraging investors to get involved to secure their investments and future rights.
See More
iRhythm Gains CDC Coverage Decision for Cardiac Monitoring Devices
- Policy Boost: The CDC's finalized local coverage determination for cardiac monitoring devices, including iRhythm's Zio ECG system, is expected to enhance market acceptance and sales potential for the company.
- Analyst Optimism: BTIG analyst Marie Thibault highlighted in a research note that this decision alleviates investor confusion regarding Medicare proposals, viewing the update as a positive for iRhythm with a Buy rating and a target price of $185.
- Market Expectations: The analyst anticipates that the other two Medicare Administrative Contractors (MACs), Palmetto and CGS, will follow suit, further strengthening iRhythm's competitive position and business stability in the market.
- Financial Outlook: iRhythm forecasts 2026 revenue between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, indicating strong growth potential supported by the new policy.
See More
iRhythm Exceeds Q1 2026 Earnings Expectations
- Significant Revenue Growth: iRhythm reported $199.4 million in revenue for Q1 2026, representing a 26% year-over-year increase that exceeded analyst expectations, demonstrating strong performance across cardiology and primary care, thereby solidifying its market position.
- Improved Adjusted EBITDA: The adjusted EBITDA margin for Q1 improved to 7.1%, reflecting an 880 basis point increase from the previous quarter, which highlights the company's success in manufacturing automation and workflow optimization, and is expected to drive future profitability enhancements.
- Market Expansion Strategy: The company achieved its best quarter in history in the U.K. while also receiving an updated reimbursement framework in Japan, indicating that its international market expansion strategy is yielding results and is likely to enhance revenue streams in the future.
- Optimistic Outlook: iRhythm raised its full-year 2026 revenue guidance to $875 million to $885 million and anticipates Q2 revenue in the range of $218 million to $220 million, reflecting management's confidence in future performance and sustained market demand.
See More
iRhythm Technologies Set to Announce Q1 Earnings on April 30
- Earnings Announcement: iRhythm Technologies is set to release its Q1 2023 earnings on April 30 after market close, with a consensus EPS estimate of -$0.64, reflecting a 32.6% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $194.09 million, representing a 22.3% year-over-year increase, which highlights the company's positive performance in market demand and product innovation, potentially driving future growth.
- Historical Performance Review: Over the past two years, iRhythm has exceeded EPS estimates 50% of the time and revenue estimates 100% of the time, demonstrating the company's reliability and execution capability in financial forecasting.
- Future Outlook: iRhythm aims for a revenue target of $870 million to $880 million by 2026 while continuing to expand its innovations in artificial intelligence and mobile cardiac telemetry (MCT), showcasing the company's confidence and strategic positioning for future growth.
See More
Investigation into iRhythm Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting shareholder rights and corporate governance.
- Legal Fee Arrangement: The firm promises to handle the case on a contingent fee basis, meaning shareholders can pursue legal remedies without incurring upfront legal costs, thereby reducing the financial risk of participation.
- Importance of Shareholder Participation: Involvement from shareholders can drive improvements in company policies and oversight mechanisms, enhancing transparency and accountability, which ultimately helps to increase shareholder value and promote long-term company growth.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its strength in protecting investor rights.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as indicated by a federal securities lawsuit alleging failure to disclose the true purpose of the Zio AT monitor.
- Disclosure Failures: The lawsuit claims that insiders at iRhythm repeatedly touted the potential growth of the Zio AT as an innovative product without clarifying that it was intended for high-risk patients, leading investors to misunderstand its market potential.
- Stock Price Impact: These misleading statements resulted in iRhythm's common stock trading at artificially inflated prices during relevant periods, potentially causing financial losses for shareholders and damaging the company's market reputation.
- Call to Action for Shareholders: Kuehn Law urges shareholders who purchased IRTC stock before November 5, 2021, to contact them promptly to assert their rights and contribute to the integrity of the financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether certain executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that insiders failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Impact of Misrepresentation: The lawsuit claims that iRhythm executives repeatedly touted the potential growth of the Zio AT as an innovative product without clarifying its primary use for high-risk patients, resulting in artificially inflated stock prices during relevant periods, which misled investors.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased IRTC stock prior to November 5, 2021, to contact their attorney promptly to protect their rights, highlighting the urgency and necessity of legal action in this matter.
- Call for Market Integrity: Kuehn Law emphasizes the importance of shareholder voices in maintaining the integrity and fairness of financial markets, encouraging investors to get involved to secure their investments and future rights.
See More
